Global Central Nervous System (CNS) Biomarkers by Country (United States, Canada, India, China, Japan, United Kingdom), Company Profiles, Share, Trends, Analysis, Opportunities, Segmentation and Forecast 2015 – 2021
A biomarker is biological feature that can be used to measure the presence or progress of disease or the effects of treatment. For example, prostate specific antigen (PSA) is a biomarker for cancer of prostate. Biomarkers enable the researchers to quickly see large number of biological analytics. The global market value of the Global CNS Biomarker market is expected to be a billion dollar opportunity by 2015.and the size of the global CNS Biomarker market is expected to increase immensely by 2021, at a solid compound annual growth rate in 2015-2021.
In the present scenario, the research and development in CNS market has paced up due to support from government and private players. Additionally, FDA approvals are giving rise to significant scope in biomarker market. Moreover, Technological advancement in the CNS biomarker diagnostics enables to expand CNS biomarker market and innovations are giving rise to growth of CNS biomarker market. Presently, the global CNS biomarker market is undergoing rapid expansion with the discovery of new applications and the development of existing technologies. The key driving forces for the global CNS biomarker market are: Development in proteomics, genomics and imaging system in CNS biomarker. Funding from government and private players has also strengthened the CNS market. Increase in government spending/ private investment in healthcare budgets and R&D respectively, rising case of lifestyle related diseases and so on. Various factors such as High cost of CNS biomarker test and diagnostics are hindrances for the growth of CNS biomarker market. Reimbursement issues have left CNS biomarker market in doldrums.
The key players in global CNS biomarker market are Abastar MDX Inc, Thermo fisher scientific, Abiant Inc, EKFdiagnostics holdings Inc, Enzo biochem Inc, Acumen pharmaceuticals Inc, Adlyfe Inc, Alseres pharmaceuticals Inc, Apitope international, Aposense, Applied neurosolutions Inc, Avacta group plc, Merc & co. Inc, Avid radiopharmaceuticals Inc, Banyan biomarkers, Diagenic ASA, Exonhit therapeutics, Genenews ltd, Glycominds ltd, Great lakes neurotechnologies, Innogenetics biological, innovative neurotechnologies Inc, Metabolon Inc, Myriad RBM Inc, Oligomerix Inc, Opko health inc, Proteome sciences products, Ridge diagnostics and so on.
Companies Profiled
1. Abastar MDX Inc
2. Thermo fisher scientific
3. Abiant Inc
4. EKFdiagnostics holdings inc
5. Enzo biochem inc
6. Acumen pharmaceuticals Inc
7. Adlyfe Inc
8. Alseres pharmaceuticals Inc
9. Apitope international
10. Aposense
11. Applied neurosolutions Inc
12. Avacta group plc
13. Merck & co inc
14. Avid radiopharmaceuticals Inc
15. Banyan biomarkers
16. Diagenic ASA
17. Exonhit therapeutics
18. Genenews ltd
19. Glycominds ltd
20. Great lakes neurotechnologies
21. Innogenetics biologicals
22. Innovative neurotechnologies inc
23. Metabolon inc
24. Myriad RBM inc
25. Oligomerix inc
26. Opko health inc
27. Osta biotechnologies inc
28. Proteome sciences products
29. Psynova neurotech ltd
30. Ridge diagnostics
31. Satori pharmaceutical inc
32. Sabiosciences
This Occams Research Report covers
1. Historical data
2. Revenue forecasts, growth rates and CAGR upto 2021
3. Industry Analysis
4. Competitive Analysis
5. Key geographic growth data
6. In-depth profiling of companies
In the present scenario, the research and development in CNS market has paced up due to support from government and private players. Additionally, FDA approvals are giving rise to significant scope in biomarker market. Moreover, Technological advancement in the CNS biomarker diagnostics enables to expand CNS biomarker market and innovations are giving rise to growth of CNS biomarker market. Presently, the global CNS biomarker market is undergoing rapid expansion with the discovery of new applications and the development of existing technologies. The key driving forces for the global CNS biomarker market are: Development in proteomics, genomics and imaging system in CNS biomarker. Funding from government and private players has also strengthened the CNS market. Increase in government spending/ private investment in healthcare budgets and R&D respectively, rising case of lifestyle related diseases and so on. Various factors such as High cost of CNS biomarker test and diagnostics are hindrances for the growth of CNS biomarker market. Reimbursement issues have left CNS biomarker market in doldrums.
The key players in global CNS biomarker market are Abastar MDX Inc, Thermo fisher scientific, Abiant Inc, EKFdiagnostics holdings Inc, Enzo biochem Inc, Acumen pharmaceuticals Inc, Adlyfe Inc, Alseres pharmaceuticals Inc, Apitope international, Aposense, Applied neurosolutions Inc, Avacta group plc, Merc & co. Inc, Avid radiopharmaceuticals Inc, Banyan biomarkers, Diagenic ASA, Exonhit therapeutics, Genenews ltd, Glycominds ltd, Great lakes neurotechnologies, Innogenetics biological, innovative neurotechnologies Inc, Metabolon Inc, Myriad RBM Inc, Oligomerix Inc, Opko health inc, Proteome sciences products, Ridge diagnostics and so on.
Companies Profiled
1. Abastar MDX Inc
2. Thermo fisher scientific
3. Abiant Inc
4. EKFdiagnostics holdings inc
5. Enzo biochem inc
6. Acumen pharmaceuticals Inc
7. Adlyfe Inc
8. Alseres pharmaceuticals Inc
9. Apitope international
10. Aposense
11. Applied neurosolutions Inc
12. Avacta group plc
13. Merck & co inc
14. Avid radiopharmaceuticals Inc
15. Banyan biomarkers
16. Diagenic ASA
17. Exonhit therapeutics
18. Genenews ltd
19. Glycominds ltd
20. Great lakes neurotechnologies
21. Innogenetics biologicals
22. Innovative neurotechnologies inc
23. Metabolon inc
24. Myriad RBM inc
25. Oligomerix inc
26. Opko health inc
27. Osta biotechnologies inc
28. Proteome sciences products
29. Psynova neurotech ltd
30. Ridge diagnostics
31. Satori pharmaceutical inc
32. Sabiosciences
This Occams Research Report covers
1. Historical data
2. Revenue forecasts, growth rates and CAGR upto 2021
3. Industry Analysis
4. Competitive Analysis
5. Key geographic growth data
6. In-depth profiling of companies
1. INTRODUCTION
1.1. Executive summary
1.2. Estimation methodology
2. MARKET OVERVIEW
2.1. Market definition and scope
2.2. Key findings
2.3. Parametric analysis
2.3.1. Prevalence & incidence rate of alzheimer’s disease
2.3.2. Hospital and research center across geographies
2.3.3. Prevalence & incidence rate of parkinson’s disease
2.3.4. Prevalence & incidence rate of cancer disease
2.3.5. Healthcare expenditure across geographies
2.4. Key market insights
2.4.1. Top 3 emerging countries
2.4.2. Top 3 revenue generating segments
2.4.3. Top growing markets and emerging trends
2.4.4. Pipeline analysis
2.4.5. Patent analysis
2.4.5.1. Patents for alzheimer’s disease biomarkers
2.4.5.2. Patents for multiple sclerosis biomarkers
2.4.5.3. Patents for parkinson’s disease biomarkers
2.4.5.4. Patents for ALS disease biomarkers
2.4.6. R&D scenario in CNS biomarker market
2.4.6.1. R&d in genomics
2.4.6.2. R&d in proteomics
2.4.6.3. Clinical trials on drug biomarkers in major CNS diseases
2.4.6.4. Clinical trials on diagnostic test biomarkers in major CNS diseases
2.5. Competitive intelligence
2.5.1. Market share analysis
2.5.2. Top winning strategies
2.5.3. Case studies: top competitive moves
2.6. Value chain analysis
2.7. Key buying criteria
2.8. Strategic recommendation
2.9. Strategic conclusions
3. MARKET DETERMINANTS
3.1. Market drivers
3.1.1. Development in proteomics, genomics and imaging system has increased demand for CNS biomarker.
3.1.2. Funding from government and private players to boost CNS biomarker market
3.1.3. Growth in life style oriented diseases
3.1.4. Growth in government and private funding in CNS biomarker market
3.1.5. Growth in public-private partnership
3.1.6. FDA approvals giving rise to significant scope in biomarker market
3.1.7. Technological advancement enables to expand CNS biomarker market
3.1.8. Innovation giving rise to growth of CNS biomarker market
3.1.9. Global increase in healthcare expenditure
3.2. Market restraints
3.2.1. High cost of CNS biomarker test and diagnostics
3.2.2. Reimbursement issues affecting the CNS biomarker market
3.3. Market challenges
3.3.1. Creating awareness for CNS biomarker market
3.3.2. Global economic slowdown may affect the CNS biomarker market
3.3.3. Technical issues of sample collection and storage
3.4. Market opportunities
3.4.1. Increasing adoption of personalized medicines
3.4.2. Untapped APAC region has huge scope for CNS biomarker market
3.4.3. Global increase in aging population has created huge scope for CNS biomarker market
3.4.4. Favorable government policies and support for CNS biomarkers
4. SECTOR ANALYSIS
4.1. Parent market
4.2. Sub-segment market
4.3. Alternative market
5. MARKET SEGMENTATION
5.1. Global CNS biomarker market
5.1.1. Global CNS biomarker market by application, 2014-2021, ($ millions)
5.1.1.1. Global diagnostic development market, 2014-2021, ($ millions)
5.1.1.2. Global drug discovery and development market, 2014-2021, ($ millions)
5.1.1.3. Global personalized medicine market, 2014-2021, ($ millions)
5.1.1.4. Global disease risk assessment market, 2014-2021, ($ millions)
5.1.1.5. Global other market, 2014-2021, ($ millions)
5.1.2. Global CNS biomarker market by type, 2014-2021, ($ millions)
5.1.2.1. Global safety biomarker market, 2014-2021, ($ millions)
5.1.2.2. Global efficacy biomarker market, 2014-2021, ($ millions)
5.1.2.2.1. Global predictive biomarker market, 2014-2021, ($ millions)
5.1.2.2.1.1., 2014-2021, ($ millions)
5.1.2.2.2. Global pharmacodynamic biomarker market, 2014-2021, ($ millions)
5.1.2.2.3. Global prognostic biomarker market, 2014-2021, ($ millions)
5.1.2.3. Global validation biomarker market, 2014-2021, ($ millions)
5.2. Global CNS biomarker by end user, 2014-2021, ($ millions)
5.2.1. Hospitals
5.2.2. Eye clinics
5.2.3. Diagnostic centers
5.2.4. Patients
6. COMPETITIVE LANDSCAPE
6.1. Market share
6.2. Strategy – An analysis across tiers
7. GEOGRAPHICAL ANALYSIS
7.1. North America CNS biomarker market, 2014-2021, ($millions)
7.1.1. United States (U.S.) CNS biomarker market, 2014-2021, ($millions)
7.1.2. Canada CNS biomarker market, 2014-2021, ($millions)
7.2. Europe CNS biomarker market, 2014-2021, ($millions)
7.2.1. United Kingdom CNS biomarker (UK) market, 2014-2021, ($millions)
7.2.2. France CNS biomarker market, 2014-2021, ($millions)
7.2.3. Germany CNS biomarker market, 2014-2021, ($millions)
7.2.4. Spain CNS biomarker market, 2014-2021, ($millions)
7.2.5. Italy CNS biomarker market, 2014-2021, ($millions)
7.2.6. RoE CNS biomarker market, 2014-2021, ($millions)
7.3. Asia Pacific CNS biomarker market, 2014-2021, ($millions)
7.3.1. India CNS biomarker market, 2014-2021, ($millions)
7.3.2. China CNS biomarker market, 2014-2021, ($millions)
7.3.3. Japan CNS biomarker market, 2014-2021, ($millions)
7.3.4. Korea CNS biomarker market, 2014-2021, ($millions)
7.3.5. Australia CNS biomarker market, 2014-2021, ($millions)
7.3.6. RoAPAC CNS biomarker market, 2014-2021, ($millions)
7.4. Rest of the world market, 2014-2021, ($millions)
7.4.1. Latin America CNS biomarker market, 2014-2021, ($millions)
7.4.2. MENA CNS biomarker market, 2014-2021, ($millions)
7.4.3. Africa CNS biomarker market, 2014-2021, ($millions)
8. COMPANY PROFILING: (OVER, SCOT ANALYSIS, STRATEGIC REVIEW)
8.1. Abastar MDX Inc
8.2. Thermo fisher scientific
8.3. Abiant Inc
8.4. EKFdiagnostics holdings inc
8.5. Enzo biochem inc
8.6. Acumen pharmaceuticals Inc
8.7. Adlyfe Inc
8.8. Alseres pharmaceuticals Inc
8.9. Apitope international
8.10. Aposense
8.11. Applied neurosolutions Inc
8.12. Avacta group plc
8.13. Merc & co. in
8.14. Avid radiopharmaceuticals Inc
8.15. Banyan biomarkers
8.16. Diagenic ASA
8.17. Exonhit therapeutics
8.18. Genenews ltd
8.19. Glycominds ltd
8.20. Great lakes neurotechnologies
8.21. Innogenetics biologicals
8.22. Innovative neurotechnologies inc
8.23. Metabolon inc
8.24. Myriad RBM inc
8.25. Oligomerix inc
8.26. Opko health inc
8.27. Osta biotechnologies inc
8.28. Proteome sciences products
8.29. Psynova neurotech ltd
8.30. Ridge diagnostics
8.31. Satori pharmaceutical inc
8.32. Sabiosciences
1.1. Executive summary
1.2. Estimation methodology
2. MARKET OVERVIEW
2.1. Market definition and scope
2.2. Key findings
2.3. Parametric analysis
2.3.1. Prevalence & incidence rate of alzheimer’s disease
2.3.2. Hospital and research center across geographies
2.3.3. Prevalence & incidence rate of parkinson’s disease
2.3.4. Prevalence & incidence rate of cancer disease
2.3.5. Healthcare expenditure across geographies
2.4. Key market insights
2.4.1. Top 3 emerging countries
2.4.2. Top 3 revenue generating segments
2.4.3. Top growing markets and emerging trends
2.4.4. Pipeline analysis
2.4.5. Patent analysis
2.4.5.1. Patents for alzheimer’s disease biomarkers
2.4.5.2. Patents for multiple sclerosis biomarkers
2.4.5.3. Patents for parkinson’s disease biomarkers
2.4.5.4. Patents for ALS disease biomarkers
2.4.6. R&D scenario in CNS biomarker market
2.4.6.1. R&d in genomics
2.4.6.2. R&d in proteomics
2.4.6.3. Clinical trials on drug biomarkers in major CNS diseases
2.4.6.4. Clinical trials on diagnostic test biomarkers in major CNS diseases
2.5. Competitive intelligence
2.5.1. Market share analysis
2.5.2. Top winning strategies
2.5.3. Case studies: top competitive moves
2.6. Value chain analysis
2.7. Key buying criteria
2.8. Strategic recommendation
2.9. Strategic conclusions
3. MARKET DETERMINANTS
3.1. Market drivers
3.1.1. Development in proteomics, genomics and imaging system has increased demand for CNS biomarker.
3.1.2. Funding from government and private players to boost CNS biomarker market
3.1.3. Growth in life style oriented diseases
3.1.4. Growth in government and private funding in CNS biomarker market
3.1.5. Growth in public-private partnership
3.1.6. FDA approvals giving rise to significant scope in biomarker market
3.1.7. Technological advancement enables to expand CNS biomarker market
3.1.8. Innovation giving rise to growth of CNS biomarker market
3.1.9. Global increase in healthcare expenditure
3.2. Market restraints
3.2.1. High cost of CNS biomarker test and diagnostics
3.2.2. Reimbursement issues affecting the CNS biomarker market
3.3. Market challenges
3.3.1. Creating awareness for CNS biomarker market
3.3.2. Global economic slowdown may affect the CNS biomarker market
3.3.3. Technical issues of sample collection and storage
3.4. Market opportunities
3.4.1. Increasing adoption of personalized medicines
3.4.2. Untapped APAC region has huge scope for CNS biomarker market
3.4.3. Global increase in aging population has created huge scope for CNS biomarker market
3.4.4. Favorable government policies and support for CNS biomarkers
4. SECTOR ANALYSIS
4.1. Parent market
4.2. Sub-segment market
4.3. Alternative market
5. MARKET SEGMENTATION
5.1. Global CNS biomarker market
5.1.1. Global CNS biomarker market by application, 2014-2021, ($ millions)
5.1.1.1. Global diagnostic development market, 2014-2021, ($ millions)
5.1.1.2. Global drug discovery and development market, 2014-2021, ($ millions)
5.1.1.3. Global personalized medicine market, 2014-2021, ($ millions)
5.1.1.4. Global disease risk assessment market, 2014-2021, ($ millions)
5.1.1.5. Global other market, 2014-2021, ($ millions)
5.1.2. Global CNS biomarker market by type, 2014-2021, ($ millions)
5.1.2.1. Global safety biomarker market, 2014-2021, ($ millions)
5.1.2.2. Global efficacy biomarker market, 2014-2021, ($ millions)
5.1.2.2.1. Global predictive biomarker market, 2014-2021, ($ millions)
5.1.2.2.1.1., 2014-2021, ($ millions)
5.1.2.2.2. Global pharmacodynamic biomarker market, 2014-2021, ($ millions)
5.1.2.2.3. Global prognostic biomarker market, 2014-2021, ($ millions)
5.1.2.3. Global validation biomarker market, 2014-2021, ($ millions)
5.2. Global CNS biomarker by end user, 2014-2021, ($ millions)
5.2.1. Hospitals
5.2.2. Eye clinics
5.2.3. Diagnostic centers
5.2.4. Patients
6. COMPETITIVE LANDSCAPE
6.1. Market share
6.2. Strategy – An analysis across tiers
7. GEOGRAPHICAL ANALYSIS
7.1. North America CNS biomarker market, 2014-2021, ($millions)
7.1.1. United States (U.S.) CNS biomarker market, 2014-2021, ($millions)
7.1.2. Canada CNS biomarker market, 2014-2021, ($millions)
7.2. Europe CNS biomarker market, 2014-2021, ($millions)
7.2.1. United Kingdom CNS biomarker (UK) market, 2014-2021, ($millions)
7.2.2. France CNS biomarker market, 2014-2021, ($millions)
7.2.3. Germany CNS biomarker market, 2014-2021, ($millions)
7.2.4. Spain CNS biomarker market, 2014-2021, ($millions)
7.2.5. Italy CNS biomarker market, 2014-2021, ($millions)
7.2.6. RoE CNS biomarker market, 2014-2021, ($millions)
7.3. Asia Pacific CNS biomarker market, 2014-2021, ($millions)
7.3.1. India CNS biomarker market, 2014-2021, ($millions)
7.3.2. China CNS biomarker market, 2014-2021, ($millions)
7.3.3. Japan CNS biomarker market, 2014-2021, ($millions)
7.3.4. Korea CNS biomarker market, 2014-2021, ($millions)
7.3.5. Australia CNS biomarker market, 2014-2021, ($millions)
7.3.6. RoAPAC CNS biomarker market, 2014-2021, ($millions)
7.4. Rest of the world market, 2014-2021, ($millions)
7.4.1. Latin America CNS biomarker market, 2014-2021, ($millions)
7.4.2. MENA CNS biomarker market, 2014-2021, ($millions)
7.4.3. Africa CNS biomarker market, 2014-2021, ($millions)
8. COMPANY PROFILING: (OVER, SCOT ANALYSIS, STRATEGIC REVIEW)
8.1. Abastar MDX Inc
8.2. Thermo fisher scientific
8.3. Abiant Inc
8.4. EKFdiagnostics holdings inc
8.5. Enzo biochem inc
8.6. Acumen pharmaceuticals Inc
8.7. Adlyfe Inc
8.8. Alseres pharmaceuticals Inc
8.9. Apitope international
8.10. Aposense
8.11. Applied neurosolutions Inc
8.12. Avacta group plc
8.13. Merc & co. in
8.14. Avid radiopharmaceuticals Inc
8.15. Banyan biomarkers
8.16. Diagenic ASA
8.17. Exonhit therapeutics
8.18. Genenews ltd
8.19. Glycominds ltd
8.20. Great lakes neurotechnologies
8.21. Innogenetics biologicals
8.22. Innovative neurotechnologies inc
8.23. Metabolon inc
8.24. Myriad RBM inc
8.25. Oligomerix inc
8.26. Opko health inc
8.27. Osta biotechnologies inc
8.28. Proteome sciences products
8.29. Psynova neurotech ltd
8.30. Ridge diagnostics
8.31. Satori pharmaceutical inc
8.32. Sabiosciences
LIST OF TABLES
1. Global CNS biomarker market by application, 2014-2021, ($ millions)
2. Global diagnostic development market, 2014-2021, ($ millions)
3. Global drug discovery and development market, 2014-2021, ($ millions)
4. Global personalized medicine market, 2014-2021, ($ millions)
5. Global disease risk assessment market, 2014-2021, ($ millions)
6. Global other market, 2014-2021, ($ millions)
7. Global CNS biomarker market by type, 2014-2021, ($ millions)
8. Global safety biomarker market, 2014-2021, ($ millions)
9. Global efficacy biomarker market, 2014-2021, ($ millions)
10. Global predictive biomarker market, 2014-2021, ($ millions)
11. Global surrogate biomarker market, 2014-2021, ($ millions)
12. Global pharmacodynamic biomarker market, 2014-2021, ($ millions)
13. Global prognostic biomarker market, 2014-2021, ($ millions)
14. Global validation biomarker market, 2014-2021, ($ millions)
15. Global CNS biomarker by end user, 2014-2021, ($ millions)
16. Global Hospitals market, 2014-2021, ($ millions)
17. Global Eye clinics market, 2014-2021, ($ millions)
18. Global Diagnostic centers market, 2014-2021, ($ millions)
19. Global Patients market, 2014-2021, ($ millions)
1. Global CNS biomarker market by application, 2014-2021, ($ millions)
2. Global diagnostic development market, 2014-2021, ($ millions)
3. Global drug discovery and development market, 2014-2021, ($ millions)
4. Global personalized medicine market, 2014-2021, ($ millions)
5. Global disease risk assessment market, 2014-2021, ($ millions)
6. Global other market, 2014-2021, ($ millions)
7. Global CNS biomarker market by type, 2014-2021, ($ millions)
8. Global safety biomarker market, 2014-2021, ($ millions)
9. Global efficacy biomarker market, 2014-2021, ($ millions)
10. Global predictive biomarker market, 2014-2021, ($ millions)
11. Global surrogate biomarker market, 2014-2021, ($ millions)
12. Global pharmacodynamic biomarker market, 2014-2021, ($ millions)
13. Global prognostic biomarker market, 2014-2021, ($ millions)
14. Global validation biomarker market, 2014-2021, ($ millions)
15. Global CNS biomarker by end user, 2014-2021, ($ millions)
16. Global Hospitals market, 2014-2021, ($ millions)
17. Global Eye clinics market, 2014-2021, ($ millions)
18. Global Diagnostic centers market, 2014-2021, ($ millions)
19. Global Patients market, 2014-2021, ($ millions)
LIST OF FIGURES
1. United States (U.S.) CNS biomarker market, 2014-2021, ($millions)
2. Canada CNS biomarker market, 2014-2021, ($millions)
3. India CNS biomarker market, 2014-2021, ($millions)
4. China CNS biomarker market, 2014-2021, ($millions)
5. Japan CNS biomarker market, 2014-2021, ($millions)
6. Korea CNS biomarker market, 2014-2021, ($millions)
7. Australia CNS biomarker market, 2014-2021, ($millions)
8. RoAPAC CNS biomarker market, 2014-2021, ($millions)
9. Latin America CNS biomarker market, 2014-2021, ($millions)
10. MENA CNS biomarker market, 2014-2021, ($millions)
11. Africa CNS biomarker market, 2014-2021, ($millions)
1. United States (U.S.) CNS biomarker market, 2014-2021, ($millions)
2. Canada CNS biomarker market, 2014-2021, ($millions)
3. India CNS biomarker market, 2014-2021, ($millions)
4. China CNS biomarker market, 2014-2021, ($millions)
5. Japan CNS biomarker market, 2014-2021, ($millions)
6. Korea CNS biomarker market, 2014-2021, ($millions)
7. Australia CNS biomarker market, 2014-2021, ($millions)
8. RoAPAC CNS biomarker market, 2014-2021, ($millions)
9. Latin America CNS biomarker market, 2014-2021, ($millions)
10. MENA CNS biomarker market, 2014-2021, ($millions)
11. Africa CNS biomarker market, 2014-2021, ($millions)
